



Please type a plus sign (+) inside this box ☒

PTO/SB/08B (10-96)
Approved through 10/31/99. OMB 0654-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



Submit for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/024,036
Filing Date	December 17, 2001
First Named Inventor	Rajasekhar Bandaru
Group Art Unit	1652
Examiner Name	David J. Steadman
Attorney Docket Number	MPI00-521P1RM

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
DJS	C1	VERPLOEGEN, S., et al. "Identification and Characterization of CKLiK: A Novel Granulocyte Ca2+/Calmodulin-Dependent Kinase" Database Submitted July 11, 2000, Dept. Pulmonary Diseases, University Medical Center Utrecht, Heidelberglaan 100, Utrecht 3584 CX, The Netherlands. EMBL-EBI Accession No. AF286366	
DJS	C2	STRAUSBERG, ROBERT, March 14, 2000. Alignment of AI923704 and SEQ ID NO: 1 show 612 contiguous nucleotide matches. National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index http://www.ncbi.nlm.nih.gov/nciegap EMBL-EBI Accession No. AI923704	

RECEIVED
JUN 12 2003
TECH CENTER 1600/2900

Examiner Signature		Date Considered	8-14-03
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here is English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

